Gufic Biosciences has made further investment of $50,000 in Selvax by way of subscription to 3,78,350 Ordinary shares at AUD 20 cents per share on April 28, 2026. The acquisition of equity shares in Selvax is a strategic arrangement for the development of immunotherapy solutions in oncology and is intended to enable the company to diversify into the healthcare and biotechnology sector and participate in the development of immunology-based treatments for large solid tumours.
The investment aligns with the company’s long-term strategy of strategic diversification and value creation, providing access to proprietary technology, research capabilities and potential commercial opportunities in both human and veterinary oncology and is expected to generate sustainable long-term benefits for the company and its stakeholders once the therapy is medically commercialised. Total number of Ordinary shares held after post-acquisition is 16,85,350 shares.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: